Millennium Pharmaceuticals Inc. has identified a homolog of angiotensin converting enzyme that the company said is not inhibited by marketed ACE inhibitors and may represent a novel target to treat hypertension and chronic heart failure (CHF). But since its function is unknown, it is not yet clear how useful the homolog will be as a therapeutic target.

MLNM last week published